Systemic Lupus Erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body, and its symptoms range from general malaise to serious, CNS and renal manifestations. Currently, there are limited treatment options available to treat the condition. Corticosteroids, hydroxychloroquine, and conventional immunosuppressants are the mainstay of treatment for SLE. However, many patients fail to respond to these therapies and/or experience significant adverse events, and clinicians utilize other agents including Benlysta (the only biologic indicated for SLE) and Rituxan (off-label).
The Treatment Algorithms: Claims Data Analysis report examines physicians’ actual prescribing behavior as they initiate therapy and move through second- and third-line choices. Our analysis is supported by a deep longitudinal patient-level claims dataset and provides a representative sample of U.S. treatment practice for Medicare supplemental and commercially insured patients.